Disparity of race reporting in US Food and Drug Administration drug approvals for urinary system cancers from 2006 to 2021

被引：3

作者：

Glover, Michael ^{[1
]}

Hui, Gavin ^{[1
]}

Chiang, Ryan ^{[1
]}

Savage, Philip ^{[2
]}

Krell, Jonathan ^{[3
]}

Julve, Maximilian ^{[3
]}

Grivas, Petros ^{[4
]}

Lythgoe, Mark ^{[3
]}

Khaki, Ali Raza ^{[5
]}

机构：

[1] Stanford Univ, Dept Med, Stanford, CA 94305 USA

[2] Brighton & Sussex Univ Hosp NHS Trust, Dept Oncol, Brighton, E Sussex, England

[3] Hammersmith Hosp, Imperial Coll London, Dept Surg & Canc, London, England

[4] Univ Washington, Fred Hutchinson Canc Res Ctr, Dept Med, Div Med Oncol,Clin Res Div, Seattle, WA USA

[5] Stanford Univ, Dept Med, Div Oncol, Stanford, CA USA

来源：

BJU INTERNATIONAL | 2022年 / 129卷 / 02期

关键词：

D O I：

10.1111/bju.15629

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：168 / 170

页数：3

共 50 条

[31] Monitoring adverse drug events: The Food and Drug Administration MedWatch reporting system
Landow, L
REGIONAL ANESTHESIA AND PAIN MEDICINE, 1998, 23 (06): : 190 - 193
[32] Reporting of immune-related adverse events (irAEs) in US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
Tapiavala, Shaili
Shenouda, Mina A.
Patel, Vaibhav G.
Davis, Andrew A.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[33] Psoriasis adverse events and associated medications as reported in the US Food and Drug Reporting System from 2016 to 2021
Learned, Christine
Alsukait, Sara
Deverapalli, Sandhya
Elliott, Erika
Moody, Katherine
Sobell, Jeffrey
Konnikov, Nellie
Ortega, Melissa
Rosmarin, David
JAAD INTERNATIONAL, 2022, 7 : 144 - 145
[34] Assessing drug lag in new drug approvals by the Iran Food and Drug Administration compared to the US FDA, EMA, and PMDA: A 20-year analysis (2001-2021)
Alipour, Sama
Parashkouhi, Sadra Nadimi
Mojahedian, Mohammadmahdi
Abbasian, Hadi
MEDICINE, 2024, 103 (25)
[35] Improving Manufacturer Reporting of Adverse Events to the US Food and Drug Administration
Redberg, Rita F.
JAMA INTERNAL MEDICINE, 2015, 175 (09) : 1566 - 1567
[36] An assessment of drug-induced rhabdomyolysis cases within the US Food and Drug Administration Adverse Event Reporting System
Bin Dayel, Faten
Alfirevic, Ana
Turner, Richard
Chadwick, Amy
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (03) : 1617 - 1618
[37] Analysis of Information on Drug Adverse Reactions Using US Food and Drug Administration Adverse Event Reporting System (FAERS)
Nango, Daisuke
Sekizuka, Tuyoshi
Goto, Makoto
Echizen, Hirotoshi
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2022, 142 (04): : 341 - 344
[38] Performance of subgrouped proportional reporting ratios in the US food and drug administration (FDA) adverse event reporting system
Dauner, Dan
Zhang, Rui
Adam, Terrence
Leal, Eleazar
Farley, Joel F.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 598 - 598
[39] Empirical estimation of under-reporting in the US Food and Drug Administration Adverse Event Reporting System (FAERS)
Alatawi, Yasser M.
Hansen, Richard A.
EXPERT OPINION ON DRUG SAFETY, 2017, 16 (07) : 761 - 767
[40] Performance of subgrouped proportional reporting ratios in the US Food and Drug Administration (FDA) adverse event reporting system
Dauner, Daniel G.
Zhang, Rui
Adam, Terrence J.
Leal, Eleazar
Heitlage, Viviene
Farley, Joel F.
EXPERT OPINION ON DRUG SAFETY, 2023, 22 (07) : 589 - 597

← 1 2 3 4 5 →